News | November 07, 2024
Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Subscribe To Our Newsletter & Stay Updated
